Abstract 200P
Background
Malignant Mixed Mullerian Tumor (MMMT) also known as carcinosarcoma is considered as a rare aggressive biphasic tumor with carcinomatous and sarcomatous elements found in postmenopausal women, uterus being the most common site, followed by cervix, vagina, and rarely adnexa or vulva. It usually presents at an advanced stage and lacks specific treatment guidelines requiring a multimodality approach with surgery and chemoradiation (CTRT) for better prognosis & outcomes. The aim was to study the patterns of failure and overall survival in patients treated with different modalities.
Methods
An observational analysis of 82 patients from the year 2015-2019 was done including demographic data such as age and ECOG status. The patients were staged based on the FIGO 2019 system after imaging and histopathological examination. The different treatment regimens with surgery and lymph node dissection (LND), CTRT used as definitive or adjuvant therapy was noted. This study shows the impact of surgery and CTRT on overall survival (OS), progression free survival (PFS) and disease specific survival (DSS) according to stage and type of treatment. We conducted Kaplan-Meier method with log-rank tests for comparison of prognostic factors with survival and Cox proportional hazard model for both univariate and multivariate analysis considering p values <0.05 to be statistically significant. The median follow-up period was 35 months (4-76).
Results
The OS rate was 37.8% with a median of 28 months (95% CI: 22.3-33.6), a better OS was present by 34 months (95% CI: 17.18-50.81) in patients who had received adjuvant CTRT, 12 months (95% CI: 9-15) with definitive CTRT, while 7 months (95% CI: 4-10) with only surgery. There was a statistically significant improvement (p-0.001) in overall survival rate by 65.5% for those who underwent both LND with radiation. The PFS rate was 58.5% with a median of 47 months; stage I-IIIC with both surgery and CTRT had a better PFS and DSS by 64.3% and 46.4% respectively (p-0.001).
Conclusions
Patients receiving stagewise combined modality approach with both surgery and CTRT for management had a significantly better OS, PFS and DSS in comparison to with only single mode of therapy.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
150P - Use of neoadjuvant chemotherapy for non-metastatic muscle-invasive bladder cancer in Asia-Pacific
Presenter: Ravindran Kanesvaran
Session: Poster viewing 03
Resources:
Abstract
Slides
151P - Neoadjuvant and adjuvant chemotherapy in muscle-invasive bladder cancer: Real-world analysis of chemotherapy use and impact on patient outcomes
Presenter: Alison Hiong
Session: Poster viewing 03
152P - An epidemiologic study on PD-L1 expression with clinical observation of initial treatment pattern in the Chinese muscle invasive urothelial bladder carcinoma patients
Presenter: Liqun Zhou
Session: Poster viewing 03
153P - Efficacy and toxicity of HER2-targeted antibody-drug conjugates (ADCs) in the treatment of metastatic urothelial cancer (mUC): A systematic review
Presenter: Tiago Padua
Session: Poster viewing 03
154P - Can urine cytology predict variants of bladder cancer?
Presenter: Hikaru Mikami
Session: Poster viewing 03
155P - Search for circulating tumor cells in patients with urothelial cancer
Presenter: Irina Kruglova
Session: Poster viewing 03
156P - The association between response to enfortumab vedotin therapy and primary tumor location in Japanese urothelial carcinoma patients
Presenter: Nozomi Hayakawa
Session: Poster viewing 03
163P - Outcomes and toxicity of fosfesterol in metastatic castration-resistant prostate cancer: Experience from a low middle income country
Presenter: Manuprasad Avaronnan
Session: Poster viewing 03
164P - F-18 PSMA-PET/CT-guided percutaneous prostate biopsy
Presenter: Rajender Kumar
Session: Poster viewing 03
165P - Real-world utilisation of upfront chemohormonal therapy in metastatic hormone-sensitive prostate cancer
Presenter: Richard Kelly
Session: Poster viewing 03